Trial Profile
Treatment of Glanzmann's Thrombasthenia: A Prospective Observational Registry
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Eptacog alfa (Primary)
- Indications Thrombasthenia
- Focus Therapeutic Use
- Acronyms GTR
- Sponsors Novo Nordisk
- 29 Oct 2020 Results of analysis assessing efficacy and safety of rFVIIa using data from Glanzmann's Thrombasthenia Registry (n=133), Novo Nordisk safety surveillance database and published literature (1 Jan 1999 to 1 Dec 2017) published in the Thrombosis and Haemostasis
- 07 Jul 2014 According to a Novo Nordisk media release, eptacog alfa (NovoSeven RT) was approved by the US FDA for the perioperative management and treatment of bleeding episodes in patients with Glanzmann's thrombasthenia.
- 13 May 2014 New trial record